SLC5A2 and heart failure: Notably, the approval for the prescription of SGLT2i for HFmrEF was only obtained in 2023, following new evidence based on the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) and the Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Preserved Ejection Fraction (EMPEROR-Preserved) trials, where SGLT2 inhibitors were shown to reduce the risk of cardiovascular death and hospitalization for worsening heart failure in patients with HFmrEF and HFpEF [40,41].